In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Circling the Wagons

Executive Summary

Whither Japan Pharma? If the last quarter's dealmaking is any hint, it's sticking pretty close to home--indeed, circling the wagons. An industry that needs to become less conservative is doing just the opposite as cost pressures increase in its home market.

You may also be interested in...



Successful Product Launches in Japan

Japan presents huge opportunities for new product launches, but Western companies often squander them, failing to understand the unique aspects and requirements of the market. They often mis-estimate the size of commercial opportunities in Japan because of the differences in epidemiology and medical practice or run into pricing problems because they've chosen the wrong local comparator product or ignored the Japanese tendency to prescribe lower doses of products. But Westerners can do better--taking advantage, for example, of the liberalization of development rules and even the possibility of DTC advertising.

Roche Continues To Make The Case For Gantenerumab In Alzheimer’s Disease

The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.

Brinavess' US Review: EU Postmarket Data Unlikely To Save Troubled AFib Drug

Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug;  FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

IV000906

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel